Fibrinogen Bergamo I (A alpha 16Arg----Cys): susceptibility towards thrombin following aminoethylation, methylation or carboxamidomethylation of cysteine residues
- PMID: 4082078
Fibrinogen Bergamo I (A alpha 16Arg----Cys): susceptibility towards thrombin following aminoethylation, methylation or carboxamidomethylation of cysteine residues
Abstract
An abnormal fibrinogen, denoted as "fibrinogen Bergamo I", has been characterized. Its defect consists in an exchange of arginine by cysteine in position 16 of the A alpha-chain, thus corresponding to that found in a number of other fibrinogen variants. The abnormal fibrinopeptide A cannot be split off by thrombin from intact fibrinogen Bergamo I. We describe three different chemical modifications of the cysteine A alpha 16, i.e. aminoethylation, methylation and carboxamidomethylation, and their effects on the susceptibility of fibrinogen Bergamo I towards thrombin attack. S-aminoethylation of the A alpha 16Cys renders the peptide bond A alpha 16-17 cleavable by thrombin. Following methylation or carboxamidomethylation, the A alpha 19-arginyl bond becomes accessible for thrombin. The chemically modified extended fibrinopeptide A can be readily separated from the normal fibrinopeptide A by HPLC. The latter two modifications are suitable alternative procedures for detecting the molecular defect A alpha 16Arg----Cys of fibrinogen.
Similar articles
-
Fibrinogen Geneva, a new case of A alpha 16 Arg----Cys dysfibrinogenaemia.Blood Coagul Fibrinolysis. 1990 Jun;1(2):139-43. Blood Coagul Fibrinolysis. 1990. PMID: 2130925
-
[Fibrinogen Bern III: a further case of hereditary fibrinogen variants with substitution A alpha 16 Arg----Cys].Schweiz Med Wochenschr. 1991 Jul 20;121(29):1068-71. Schweiz Med Wochenschr. 1991. PMID: 1891701 German.
-
Fibrinogen Kiel: a congenital dysfibrinogenaemia with (A alpha-16 Arg----His) substitution characterized by HPLC without prior isolation of fibrinogen.Blood Coagul Fibrinolysis. 1991 Aug;2(4):501-6. Blood Coagul Fibrinolysis. 1991. PMID: 1768762
-
The fibrinogenopathies.Ann Clin Lab Sci. 1978 May-Jun;8(3):234-8. Ann Clin Lab Sci. 1978. PMID: 350125 Review.
-
Genetically abnormal fibrinogens--strategies for structure elucidation, including fibrinopeptide analysis.Curr Probl Clin Biochem. 1984;14:273-320. Curr Probl Clin Biochem. 1984. PMID: 6391842 Review. No abstract available.
Cited by
-
Abnormal fibrinogen with an Aα 16Arg → Cys substitution is associated with multiple cerebral infarctions.J Thromb Thrombolysis. 2018 Oct;46(3):409-419. doi: 10.1007/s11239-018-1689-z. J Thromb Thrombolysis. 2018. PMID: 29869737 Review.
-
Fibrinogen Stony Brook, a heterozygous A alpha 16Arg----Cys dysfibrinogenemia. Evaluation of diminished platelet aggregation support and of enhanced inhibition of fibrin assembly.J Clin Invest. 1989 Jul;84(1):295-304. doi: 10.1172/JCI114154. J Clin Invest. 1989. PMID: 2738154 Free PMC article.
-
Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine).J Clin Invest. 1992 May;89(5):1375-81. doi: 10.1172/JCI115725. J Clin Invest. 1992. PMID: 1569180 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical